7/31/2019 Reporting Serious Adverse Events

1/4

www.healthlawyers.org

I , SC A E (SCAE) , , zk ,

j . T I H I z SCAE x / .1 I , b z ,

SCAE. I z SCAE, . A SCAE j, k k b b k b

SCAE.

Pre-disclosure Considerations

H b ?

H b SCAE q ()

? W b x b?

Considerations in the Disclosure of Serious Clinical Adverse Events

W b k

SCAE b ?

I q, SCAE, b k ,

?

H () SCAEb , q b , ?

7/31/2019 Reporting Serious Adverse Events

2/4

Considerations in the Disclosure of Serious Clinical Adverse Events

D SCAE NE2 b C M M S (CMS) bj -b b M? A, SCAE bj b b

M N E , b b b ?

I SCAE N E, q bb ?

H R C A b ? H SCAE b , , ?

Mandatory Disclosures

H SCAE b k , b ? I , b () SCAE ?

I SCAE b , , ? W

() b b ()?

D b SCAE / , , q b ?I b, q b, / SCAE

()?

D SCAE , , SCAE b U.S. F D A (FDA) S M DA3?

H b k , ?

D b x b q x b b ?

W b b ?

I SCAE , , ,IV b x b x b b ?

Disclosure to Patient and/or Patients Family

H / b k b ?

W x b x / bb b

b bq ?

H ( x ) / b k , b ?

H SCAE / ()?

H () b ?

W () b / ?

2012 A H L A

7/31/2019 Reporting Serious Adverse Events

3/4

D z ( z ) SCAE ?

H / b R C A?

I b b q b SCAE / , x b b bq ?

I , b , b ?

W / b :

. M

b. I

. P bk

. P-

. I

. R

. H

. W

. E-

j. D

k. Mb

. Q /

. O SCAE b

I / , / b - , , , , ?

W / b , , b b k , b ?

W b b , q?

W b b ()?

I q , z b b z?

I b / SCAE ()?

I k / , x

b b b ?

I / j , b () b ?

I j, b q?

W b - b?

W -

b?

2012 A H L A

Considerations in the Disclosure of Serious Clinical Adverse Events

7/31/2019 Reporting Serious Adverse Events

4/4

A () b b () , , b ()?

H / b ?

H b x b ( z)?

W b b bj ?

Voluntary Disclosures to Accrediting Bodies, the

Media or Other Third Parties

H q SCAE b (.., T JC) b / ?

I SCAE b, SCAE ()?

H b , b b k , b ?

W - b ?

D z ( z ) SCAE

?

H SCAE b, (), () b ?

D z ( z) SCAE b ?

The author, Elisabeth Belmont, Esq., of MaineHealth,

Portland, ME wishes to thank James W. Boswell, Esq., King

and Spalding, LLP, Atlanta, GA; Jay A. Martus, Esq.,

Sheridan Healthcare Inc., Sunrise, FL; and Sandra L.

Parker, Esq., Maine Hospital Association, Augusta, ME for

serving as peer reviewers for this publication.

1 SeeC J., F F., S K., Cb M.J., Respectul Management o Serious Clinical Adverse Events

(S E) (I H I), 14.

2 U.S. Dept o Health & Human Servs., Oice o Inspector General, Adverse Events in Hospitals: Overview o

Key Issues 16 (2008), available at://..///-06-07-00470. (OIG Adverse Events Overview

Report). F -q (HAC), CMS b ://../HAqC/06_H-Aq_C.#TOP.

3 S M D A 1990, Pb. L. N. 101-629, 104 S. 4511 (1990)( 21 U.S.C. 301 42 U.S.C.

263b- (1994).

2012 A H L A

T A H L A , 501()(3) z f. ..

Considerations in the Disclosure of Serious Clinical Adverse Events